Israel Englander’s Alpine Immune Sciences Inc ALPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-14,438
Closed -$572K 6743
2024
Q1
$572K Sell
14,438
-258,628
-95% -$7.63M ﹤0.01% 4728
2023
Q4
$5.2M Buy
273,066
+190,140
+229% +$2.64M ﹤0.01% 2755
2023
Q3
$950K Sell
82,926
-33,249
-29% -$409K ﹤0.01% 4221
2023
Q2
$1.19M Buy
+116,175
New +$1.05M ﹤0.01% 3907
2021
Q2
Sell
-96,017
Closed -$1.02M 7268
2021
Q1
$1.02M Buy
96,017
+50,246
+110% +$626K ﹤0.01% 4210
2020
Q4
$577K Sell
45,771
-287
-0.6% -$2.82K ﹤0.01% 4090
2020
Q3
$405 Buy
+46,058
New +$421K ﹤0.01% 3679
2018
Q4
Sell
-10,694
Closed -$68K 4280
2018
Q3
$68K Buy
+10,694
New +$74.8K ﹤0.01% 3778
2018
Q2
Sell
-13,705
Closed -$110K 4274
2018
Q1
$110K Sell
13,705
-4,567
-25% -$45.1K ﹤0.01% 3472
2017
Q4
$205K Buy
+18,272
New +$199K ﹤0.01% 3522
2017
Q2
Sell
-15,134
Closed -$177K 3966
2017
Q1
$177K Buy
15,134
+5,113
+51% +$51.8K ﹤0.01% 3239
2016
Q4
$90K Buy
+10,021
New +$200K ﹤0.01% 3208
2015
Q4
Sell
-3,572
Closed -$185K 3845
2015
Q3
$185K Buy
+3,572
New +$235K ﹤0.01% 3140

Israel Englander's ALPN Position: Q2 2024 in Review

Israel Englander sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 14,438 shares — an estimated $572K sold.

Israel Englander first reported a position in ALPN in Q3 2015 and held it in 13 quarters. The position peaked at $5.2M in Q4 2023. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

  • Israel Englander reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
  • Israel Englander sold 14,438 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $572K.
  • Israel Englander first reported a position in Alpine Immune Sciences Inc in Q3 2015 and held it in 13 quarters.
  • Israel Englander's Alpine Immune Sciences Inc position peaked at $5.2M in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.